Investment
Features
FeesSafety
Academy
More
Pluang+

Compare State Street SPDR S&P Biotech ETF (XBI) vs State Street Technology Select Sector SPDR ETF (XLK) Price & Performance

State Street SPDR S&P Biotech ETFTrade
State Street Technology Select Sector SPDR ETFTrade

Price performance (Past 24H)

Key statistics

State Street SPDR S&P Biotech ETF vs State Street Technology Select Sector SPDR ETF — how do they compare? State Street SPDR S&P Biotech ETF trades at $159.93, while State Street Technology Select Sector SPDR ETF trades at $188. Which is the better fit depends on your goals.

XBIXLK
Sector
Broad Market / FactorSector/Thematic
52-Week High
$169.55$198.21
52-Week Low
$93.43$127.49

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

State Street SPDR S&P Biotech ETF

XBI trades at $161.97, down 1.12% today, with technical indicators showing mixed signals amid a bearish overall trend. The ETF holds over 150 biotech companies and has rallied 76% in the past year, driven by M&A activity and positive clinical trial catalysts. Analyst coverage remains limited with a single hold rating, while recent news highlights sector optimism around cancer vaccine breakthroughs and improved capital access.

Outlook remains cautiously optimistic with potential for 8-14% returns over 6-12 months, though high volatility and regulatory risks persist. Key opportunities include ongoing pharmaceutical M&A and innovation in immunotherapy, while risks center on sector-specific volatility and policy uncertainty.

State Street Technology Select Sector SPDR ETF

XLK trades at $187.87, up 0.3% today, with a bullish technical signal from moving averages and support at $185. The ETF holds a concentrated mega-cap tech strategy with a low 0.08% expense ratio, though key financial ratios are unavailable. Recent news highlights sector inflows and AI-driven software shifts.

Outlook is supported by tech sector momentum and AI adoption, but risks include high concentration in top holdings and valuation sensitivity. Analysts favor XLK for its cost efficiency and exposure to AI growth, yet investors face volatility from economic and competitive pressures.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About State Street SPDR S&P Biotech ETF

XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.

Read more on XBI

About State Street Technology Select Sector SPDR ETF

XLK tracks the Technology Select Sector Index, providing targeted exposure to the largest and most influential technology companies within the S&P 500. It is a highly concentrated, liquid vehicle focused on software, semiconductors, and hardware leaders, serving as the primary benchmark for U.S. large-cap technology performance.

Read more on XLK